WallStreetZenWallStreetZen

NASDAQ: SABS
Sab Biotherapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

SABS past revenue growth

How has SABS's revenue growth performed historically?
Company
-90.63%
Industry
143.99%
Market
17.8%
SABS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
SABS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
SABS's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

SABS earnings and revenue history

Current Revenue
$2.2M
Current Earnings
-$42.2M
Current Profit Margin
-1,884.5%

SABS Return on Equity

Current Company
-144.7%
Current Industry
-63.5%
Current Market
188%
SABS's Return on Equity (-144.7%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when SABS announces earnings.

SABS Return on Assets

Current Company
-88.6%
Current Industry
2.9%
SABS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

SABS Return on Capital Employed

Current Company
-57.27%
Current Industry
19.5%
SABS's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

SABS vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
SABS$2.24M-$38.13M-$42.19M-8.24%N/A
APLM$0.00-$171.77M-$172.60MN/AN/A
NXTC$0.00-$58.47M-$62.72M-100.00%N/A
OKYO$0.00-$13.18M-$13.27MN/AN/A
NTRB$2.09M-$5.09M-$5.49M+53.43%N/A
View Top Biotech Stocks

SABS earnings dates

Next earnings date
Jun 28, 2024

Sab Biotherapeutics Earnings & Revenue FAQ

What were SABS's earnings last quarter?

On Invalid Date, Sab Biotherapeutics (NASDAQ: SABS) reported Q4 2023 earnings per share (EPS) of -$3.84, up 112.15% year over year. Total Sab Biotherapeutics earnings for the quarter were -$22.86 million. In the same quarter last year, Sab Biotherapeutics's earnings per share (EPS) was -$1.81.

If you're new to stock investing, here's how to buy Sab Biotherapeutics stock.

What was SABS's earnings growth in the past year?

As of Q2 2024, Sab Biotherapeutics's earnings has grown year over year. Sab Biotherapeutics's earnings in the past year totalled -$42.19 million.

What is SABS's earnings date?

Sab Biotherapeutics's earnings date is Invalid Date. Add SABS to your watchlist to be reminded of SABS's next earnings announcement.

What was SABS's revenue last quarter?

On Invalid Date, Sab Biotherapeutics (NASDAQ: SABS) reported Q4 2023 revenue of $305.01 thousand up 85.88% year over year. In the same quarter last year, Sab Biotherapeutics's revenue was $2.16 million.

What was SABS's revenue growth in the past year?

As of Q2 2024, Sab Biotherapeutics's revenue has grown -90.63% year over year. This is 234.62 percentage points lower than the US Biotechnology industry revenue growth rate of 143.99%. Sab Biotherapeutics's revenue in the past year totalled $2.24 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.